Aim: The purpose of the present review was to determine the clinical effect of the use of bioactive agents for the treatment of intraosseous and furcation defects. Materials & Methods: The effectiveness of the bioactive agents was evaluated when used in addition to open flap debridement (OFD) either alone or in association with grafts and/or GTR. Among the included agents, recombinant platelet-derived growth factor-BB (rhPDGF-BB), platelet-rich plasma (PRP), commercially-available enamel matrix derivative (cEMD) and peptide P-15 (P-15) have been clinically tested for treating periodontal defects. Results and Conclusions: The results of the present review indicate that: 1) cEMD either alone or in combination with grafts can be effectively used to treat intraosseous defects and clinical results appear to be stable long-term; 2) the additional use of a graft seems to enhance the clinical outcome of cEMD; 3) the combined use of rhPDGF-BB and P-15 with a graft biomaterial has shown beneficial effects in intraosseous defects; 4) contrasting results were reported for PRP and graft combinations; 5) limited evidence supports the use of bioactive agents either alone or in association with graft/GTR for the treatment of furcation defects.
Clinical outcomes with bioactive agents alone or in combination with grafting or guided tissue regeneration.
TROMBELLI, Leonardo;FARINA, Roberto
2008
Abstract
Aim: The purpose of the present review was to determine the clinical effect of the use of bioactive agents for the treatment of intraosseous and furcation defects. Materials & Methods: The effectiveness of the bioactive agents was evaluated when used in addition to open flap debridement (OFD) either alone or in association with grafts and/or GTR. Among the included agents, recombinant platelet-derived growth factor-BB (rhPDGF-BB), platelet-rich plasma (PRP), commercially-available enamel matrix derivative (cEMD) and peptide P-15 (P-15) have been clinically tested for treating periodontal defects. Results and Conclusions: The results of the present review indicate that: 1) cEMD either alone or in combination with grafts can be effectively used to treat intraosseous defects and clinical results appear to be stable long-term; 2) the additional use of a graft seems to enhance the clinical outcome of cEMD; 3) the combined use of rhPDGF-BB and P-15 with a graft biomaterial has shown beneficial effects in intraosseous defects; 4) contrasting results were reported for PRP and graft combinations; 5) limited evidence supports the use of bioactive agents either alone or in association with graft/GTR for the treatment of furcation defects.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
